Gilead Sciences Inc.

2026-10-30 20:03; UTC

Gilead Sciences rises after UBS sets a price target of $195, Wells Fargo increases to $190, and Needham establishes a new target of $200.

2026-10-29 23:02; UTC

Gilead Sciences reports Q3 adjusted EPS of $2.55 and total revenues of $8.3 billion, raising full-year product sales guidance amid lowered EPS outlook.

2026-10-28 23:01; UTC

Gilead Sciences, Inc. is advancing in after-market trading, having gained significantly since Wednesday's close and currently positioned above its 20-day moving average.

2026-10-27 23:06; UTC

Gilead Sciences, Inc. shares are trading modestly lower in after-market hours following a notable dip earlier in the session, remaining below its earlier high.

2026-10-26 23:11; UTC

Gilead Sciences, Inc. shares are declining in after-market trading, retracing to their lowest point of the day.

2026-10-23 20:07; UTC

Gilead Sciences announces a clinical trial collaboration with BioNTech to evaluate pumitamig with Trodelvy for treating PD-L1 low or negative triple-negative breast cancer.

2026-10-22 23:36; UTC

Gilead Sciences announces a $1.275 billion agreement to acquire HCXT-2001 from PepStar Therapeutics, targeting immune-mediated inflammatory diseases.

2026-10-21 23:02; UTC

Gilead Sciences, Inc. is trading higher in after-market hours, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

2026-10-20 19:46; UTC

Gilead Sciences advances after B of A Securities maintained its Buy rating and raised the price target to $172, alongside positive mid-stage trial results for ulcerative colitis.

2026-10-19 20:07; UTC

Gilead Sciences reported positive 12-week data from its Phase 2 SWIFT trial for emvistegrast, showing a 66% clinical response in patients.

2026-10-16 20:07; UTC

Gilead Sciences, Inc. shares are declining, continuing a downward trend since Thursday, with today's trading reaching a low point around mid-afternoon.

2026-10-15 23:01; UTC

Gilead Sciences, Inc. is experiencing a modest increase in after-market trading, remaining well above its 20-day moving average and near the upper end of its one-month range.

2026-10-14 23:41; UTC

Gilead Sciences, Inc. shares advanced in after-market trading, maintaining a position above recent averages and near the upper end of its one-month range.

2026-10-13 20:07; UTC

Gilead Sciences, Inc. shares fell sharply, finishing lower from Monday's close after a significant midday dip, reflecting unusual weakness in performance.

2026-10-12 23:31; UTC

Gilead Sciences, Inc. shares advanced in after-market trading, recovering from an earlier low and remaining above its 20-day moving average.

2026-10-09 19:51; UTC

Gilead Sciences, Inc. is trading sharply higher, reaching a peak cumulative return of 2.73% and remaining well above its 20-day moving average.

2026-10-08 20:07; UTC

Gilead Sciences shares advanced after RBC Capital raised its price target to $126.00 from $123.00, maintaining a Sector Perform rating.

2026-10-07 20:07; UTC

Gilead Sciences shares are advancing as JP Morgan raised its price target to $170, while Truist increased its target to $158 amid mixed analyst revisions.

2026-10-06 23:20; UTC

Gilead Sciences, Inc. is trading modestly lower in after-market hours, continuing a downward trend amid broader weakness in the biotechnology sector.

2026-10-05 19:16; UTC

Gilead Sciences, Inc. shares declined to a six-week low following CEO Daniel O'day's sale of 15k shares and news of a collaboration extension with Nurix Therapeutics.

2026-10-02 19:35; UTC

Gilead Sciences, Inc. shares fell sharply after peaking earlier, declining significantly below its 20-day moving average and continuing a trend of lower daily closes.

2026-10-01 23:00; UTC

Gilead Sciences, Inc. is trading modestly higher in after-market hours, continuing an upward trend since Thursday's close after three consecutive daily declines.

2026-09-30 19:51; UTC

Gilead Sciences, Inc. shares fell amid increased bearish sentiment, with put volume reaching 6.35k contracts and a Put/Call Ratio of 3.18.

2026-09-29 20:07; UTC

Gilead Sciences, Inc. shares fell sharply after peaking early in the day, closing lower but remaining above the 20-day moving average.

2026-09-28 19:35; UTC

Gilead Sciences, Inc. is trading higher as online commentary highlights its performance at a key technical level, remaining above the 20-day moving average.

2026-09-25 19:46; UTC

Gilead Sciences, Inc. is trading slightly higher, near the upper end of its one-month range, after earlier fluctuations during Friday's market hours.

2026-09-24 23:01; UTC

Gilead Sciences, Inc. has recorded modest gains in after-market hours following three consecutive lower daily closes, despite remaining above its 20-day moving average.

2026-09-22 20:07; UTC

Gilead Sciences, Inc. has advanced during Tuesday's trading, gaining ground since Monday's close, despite earlier pulling back from a session high.

2026-09-21 22:30; UTC

Gilead Sciences, Inc. is trading modestly lower in after-market hours, slightly below its opening level from the regular session following earlier gains.

2026-09-18 22:21; UTC

Gilead Sciences, Inc. is experiencing higher after-market trading, supported by a broadly advancing market, despite earlier session pullbacks and macroeconomic concerns.